Readoutin 13d
Gilead Sciences — Sacituzumab Govitecan-hziy
Phase 3 primary completion: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC).
- Date
- Dec 2026
- Type
- Readout
- Indication
- Metastatic Breast Cancer
Readoutin 13d
Phase 3 primary completion: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.